AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16498362
Drug: Aromatase inhibitors
RxNorm normalized name: Aromatase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase inhibitors (AIs) such as Anastrozole, Letrozole, and Exemestane
Trial: 12175374
Drug: ITI implants
RxNorm normalized name: Arthur Itis
DrugBank: Trolamine salicylate (DB11079)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ITI implants
Trial: 3931144
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg d,l-amphetamine
Trial: 24887013
Drug: Plant sterols
RxNorm normalized name: Plant Sterols/Stanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant sterols (2 g daily)
Trial: 20624140
Drug: Propofol 1
RxNorm normalized name: propofol 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 1 mg/kg IV followed by 0.5 mg/kg every 3 minutes as needed
Trial: 20624140
Drug: Ketamine 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 1.0 mg/kg IV followed by 0.5 mg/kg every 3 minutes as needed
Trial: 17898702
Drug: Mesenchymal stem
RxNorm normalized name: Human mesenchymal stem cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesenchymal stem cell therapy (MSCs)
Trial: 9489908
Drug: Omeprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (40 mg twice daily) and Amoxicillin (750 mg three times daily)
Trial: 9489908
Drug: Omeprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (40 mg twice daily) and Placebo (750 mg three times daily)
Trial: 7917910
Drug: Cisplatinum (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatinum (50 mg m‐2) with ondansetron (8 mg i.v. x 3 at chemotherapy and 8 mg p.o. x 3 for 5 days)
Trial: 7917910
Drug: Low or
RxNorm normalized name: Milkflow oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low or moderately emetogenic chemotherapy
Trial: 31648988
Drug: Mesenchymal stem
RxNorm normalized name: Human mesenchymal stem cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesenchymal stem cell injections (MSCs)
Trial: 28514784
Drug: Intensive statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive statin therapy (80 mg of rosuvastatin loading followed by 40 mg daily)
Trial: 28514784
Drug: Standard statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard statin therapy (usual-care group)
Trial: 28514784
Drug: Intensive statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive statin therapy (in patients with abnormal glucose tolerance)
Trial: 28514784
Drug: Standard statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard statin therapy (in patients with abnormal glucose tolerance)
Trial: 25931419
Drug: Actazin high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Actazin high dose (Actazin-H) [2400 mg/day]
Trial: 25931419
Drug: Gold [2400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gold [2400 mg/day]
Trial: 25931419
Drug: Actazin low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Actazin low dose (Actazin-L) [600 mg/day]
Trial: 23743088
Drug: TREAT decision
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TREAT decision support system for antibiotic treatment (intervention arm)
Trial: 21983496
Drug: Sedative/hypnotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sedative/hypnotics
Trial: 28475816
Drug: Anakinra (recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anakinra (recombinant human IL-1 receptor antagonist)
Trial: 18206361
Drug: FSC 250/50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FSC 250/50 mcg once daily
Trial: 18206361
Drug: FP 250
RxNorm normalized name: Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rIX-FP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FP 250 mcg once daily
Trial: 18206361
Drug: FSC 100/50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FSC 100/50 mcg twice daily
Trial: 16529615
Drug: Levetiracetam (LEV)
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levetiracetam (LEV) 500 mg bid, titrated to 1,000 mg bid
Trial: 23625113
Drug: Losartan (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (100 mg once daily)
Trial: 9303380
Drug: Fluconazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (400 mg once daily on days 16-30)
Trial: 9303380
Drug: Delavirdine mesylate
RxNorm normalized name: Delavirdine Mesylate
DrugBank: Delavirdine (DB00705)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delavirdine mesylate (300 mg every 8 hours for 30 days)
Trial: 8417428
Drug: Cefixime (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefixime (8 mg/kg/day daily)
Trial: 8417428
Drug: Cefaclor (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor (40 mg/kg/day divided into two doses)
Trial: 3752963
Drug: AM3 (biological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AM3 (biological response modifier) with adjuvant radiotherapy and chemotherapy
Trial: 3752963
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (adjuvant radiotherapy and chemotherapy without AM3)
Trial: 29943350
Drug: Rivaroxaban 15
RxNorm normalized name: rivaroxaban 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 15 mg once daily plus a P2Y12 inhibitor (N=696)
Trial: 29943350
Drug: Rivaroxaban 2.5
RxNorm normalized name: rivaroxaban 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 2.5 mg twice daily plus dual antiplatelet therapy (DAPT) (N=706)
Trial: 29943350
Drug: Warfarin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin plus DAPT (N=697)
Trial: 25130629
Drug: Liquid nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid nutritional supplement (Nutrisen) with increased whey protein (200 ml daily for 8 weeks)
Trial: 25130629
Drug: Liquid nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid nutritional supplement (Nutrisen)
Trial: 20937162
Drug: C. longa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C. longa (6 g)
Trial: 18782799
Drug: Trabeculectomy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trabeculectomy with low-dosage Mitomycin-C (MMC) (0.2 mg/ml, 2 min application)
Trial: 18782799
Drug: Trabeculectomy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trabeculectomy with low-dosage Mitomycin-C (MMC)
Trial: 18782799
Drug: Trabeculectomy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trabeculectomy with balanced saline solution (BSS)
Trial: 12528105
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (after 3 months for both groups)
Trial: 10494965
Drug: New split
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New split influenza vaccine derived from BV-5F1 cell line
Trial: 3492975
Drug: Diltiazem (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (various doses)
Trial: 6415780
Drug: Minocycline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline (100 mg every 12 hr for five days)
Trial: 6415780
Drug: Second cycle
RxNorm normalized name: 60 Second
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second cycle of minocycline followed by group C polysaccharide vaccine
Trial: 29907485
Drug: MCV (measles-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCV (measles-containing vaccine)
Trial: 29907485
Drug: MCV2 (second
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCV2 (second dose of measles-containing vaccine)
Trial: 27631634
Drug: Epidural (EP)
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural (EP) administration of ropivacaine every 6 hours
Trial: 27631634
Drug: Continuous wound
RxNorm normalized name: Uniphyllin Continus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous wound infusion (SC) of ropivacaine after a bolus dose for 48 hours
Trial: 17427615
Drug: Well-equipped eye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Well-equipped eye tray including fluorescein dye, materials for irrigation and foreign body removal, a short‐acting mydriatic agent, and topical anesthetics and antibiotics; prepared in advance for eye injuries.
Trial: 12452939
Drug: Ranitidine bismuth
RxNorm normalized name: RANITIDINE BISMUTH CITRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine bismuth citrate (400 mg), amoxicillin (1000 mg), metronidazole (400 mg)
Trial: 12452939
Drug: Omeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (20 mg), amoxicillin (1000 mg), metronidazole (400 mg)
Trial: 7061155
Drug: Subcutaneous injections
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injections of high molecular weight proteinaceous impurities (0.1-10 micrograms of antigen) in rabbits
Trial: 7061155
Drug: Repeated subcutaneous
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated subcutaneous injections of high molecular weight proteinaceous impurities in rabbits
Trial: 30099602
Drug: Ciprofloxacin and
RxNorm normalized name: ciprofloxacin and ornidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin and G-CSF
Trial: 25721187
Drug: Olanzapine/Fluoxetine combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine/Fluoxetine combination (OFC) 6/25-12/50 mg/day
Trial: 25721187
Drug: Olanzapine/Fluoxetine combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine/Fluoxetine combination (OFC)
Trial: 23484632
Drug: Hydrocortisone administration
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone administration during sleep
Trial: 19884625
Drug: PDE‐5 inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDE‐5 inhibitors (sildenafil, vardenafil, tadalafil, mirodenafil, udenafil)
Trial: 19884625
Drug: Choice of
RxNorm normalized name: HYDROGEN PEROXIDE 30 mg in 1 mL TOPICAL LIQUID [MediChoice of Hydrogen Peroxide 3 10 Volume]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Choice of specific PDE‐5 inhibitor
Trial: 19884625
Drug: Hormonal blood
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal blood tests or hormonal treatment
Trial: 17333244
Drug: Glucose ingestion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose ingestion (CHO trial; 0.7 g CHO kg(‐1) h(‐1))
Trial: 15496345
Drug: Muscle relaxation
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Muscle relaxation therapy (once a week for a total of 4 times)
Trial: 15496345
Drug: Ordinary daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ordinary daily life in the reformatory (Control)
Trial: 1286053
Drug: Epinephrine (1:200,000,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine (1:200,000, 5 micrograms/ml)
Trial: 30409776
Drug: Azacitidine 75
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azacitidine 75 mg/m2 days 1 to 7 intravenously or subcutaneously with nivolumab 3 mg/kg intravenously on days 1 and 14, every 4 to 6 weeks
Trial: 30409776
Drug: Azacitidine and
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azacitidine and nivolumab therapy
Trial: 29737955
Drug: Barium sulfate
RxNorm normalized name: Barium Sulfate
DrugBank: Barium (DB12481)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Barium sulfate suspension
Trial: 27036390
Drug: Spironolactone 25
RxNorm normalized name: spironolactone 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone 25 mg daily for 2 weeks
Trial: 27036390
Drug: Ibuprofen 1200
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 1200 mg daily for 2 weeks
Trial: 27036390
Drug: Cold compresses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold compresses 2 times daily for 2 weeks
Trial: 24742662
Drug: Self-titration algorithm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-titration algorithm adjusting lispro every day (Q1D)
Trial: 24742662
Drug: Self-titration algorithm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-titration algorithm adjusting lispro every 3 days (Q3D)
Trial: 24106244
Drug: Azithromycin monotherapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin monotherapy, orally
Trial: 18754834
Drug: Antidepressants given
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressants given in addition to a mood stabilizer
Trial: 11007104
Drug: Lactulose 30‐60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactulose 30‐60 ml/day for three months (SHE‐L)
Trial: 11007104
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (no lactulose, SHE‐NL)
Trial: 6933705
Drug: 0.5% NaF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% NaF solution rinsed once every 2 weeks for 3 years
Trial: 6933705
Drug: 0.2% NaF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% NaF solution rinsed weekly
Trial: 29066245
Drug: Neostigmine (0.04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine (0.04 mg kg−1)
Trial: 29066245
Drug: Edrophonium (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edrophonium (0.5 mg kg−1)
Trial: 24113432
Drug: Contrast medium
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast medium with 300 mg iodine/ml
Trial: 24113432
Drug: Contrast medium
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast medium with 370 mg iodine/ml
Trial: 19222610
Drug: Ezetimibe/simvastatin 10/20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe/simvastatin 10/20 mg
Trial: 19758618
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg zoledronic acid intravenously every 3 months for 4 treatments
Trial: 11561564
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg once daily for 2 weeks plus amoxicillin 500 mg and metronidazole 500 mg twice daily for one week (Group A)
Trial: 11561564
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg once daily for 2 weeks plus clarithromycin 250 mg and metronidazole 500 mg twice daily for one week (Group B)
Trial: 11561564
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg once daily for 2 weeks plus amoxicillin 500 mg and clarithromycin 250 mg twice daily for one week (Group C)
Trial: 11561564
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg once daily for 2 weeks plus amoxicillin 500 mg and clarithromycin 250 mg twice daily for 2 weeks (Group D)
Trial: 11561564
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg once daily for 2 weeks plus amoxicillin 500 mg and clarithromycin 500 mg twice daily for 2 weeks (Group E)
Trial: 7717629
Drug: Cochlear implants
RxNorm normalized name: Cochlearia officinalis leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cochlear implants (Ineraid, Nucleus, or 3M/Vienna)
Trial: 2197091
Drug: Norfloxacin 400
RxNorm normalized name: norfloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfloxacin 400 mg twice daily for 2 weeks
Trial: 2197091
Drug: Cefadroxil 1
RxNorm normalized name: CEFADROXIL 1GM TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefadroxil 1 g twice daily for 2 weeks
Trial: 6243714
Drug: Topical ether
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ether
Trial: 23602059
Drug: Diesel exhaust
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diesel exhaust (particle concentration 300 μg/m3)
Trial: 17901955
Drug: FOLFIRINOX (oxaliplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRINOX (oxaliplatin 85 mg/m², irinotecan 180 mg/m², leucovorin 400 mg/m², bolus fluorouracil 400 mg/m², fluorouracil 46‐h continuous IV infusion 2,400 mg/m², every 2 weeks for a maximum of 12 cycles)
Trial: 15753743
Drug: 6 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mL/kg predicted body weight tidal volume
Trial: 10845393
Drug: BCNU +
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BCNU + 40 mg tamoxifen (group B)
Trial: 10845393
Drug: BCNU +
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BCNU + 100 mg tamoxifen (group C)
Trial: 1827378
Drug: Zn‐soluble combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zn‐soluble combination
Trial: 31907649
Drug: Standardized physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized physical therapy group (SPTG)
Trial: 27886522
Drug: Intranasal ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal ketamine (100mg)
Trial: 21293122
Drug: 1,100 ppm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,100 ppm F (as NaF) dentifrice, brushed twice daily for 1 min for 4 weeks
Trial: 21293122
Drug: 1,100 ppm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,100 ppm F (as NaF) dentifrice, brushed twice daily for 1 min for 3 weeks
Trial: 16845641
Drug: Duloxetine 60
RxNorm normalized name: duloxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 60 mg/day, titrated to 90 mg/day after 1 week, then to 120 mg/day after another week, maintained for 4 weeks
Trial: 16845641
Drug: Duloxetine 60
RxNorm normalized name: duloxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 60 mg/day, 90 mg/day, 120 mg/day
Trial: 11099373
Drug: Caffeine 6
RxNorm normalized name: caffeine 65 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 6 mg á kg‐1 body mass
Trial: 11099373
Drug: Caffeine 9
RxNorm normalized name: multivit,calcium,min/ferrous fum/folic acid/guarana/caffeine 9 mg iron-400 mcg-200 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 9 mg á kg‐1 body mass
Trial: 3523711
Drug: Bismuth subsalicylate
RxNorm normalized name: Bismuth Subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bismuth subsalicylate (BSS) in high dose (2.1 g daily)
Trial: 3523711
Drug: Bismuth subsalicylate
RxNorm normalized name: Bismuth Subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bismuth subsalicylate (BSS) in low dose (1.05 g daily)
Trial: 24953914
Drug: N-acetylcysteine nebulized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine nebulized therapy
Trial: 21873370
Drug: Intraoperative goal-directed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative goal-directed fluid therapy (GDT) with oesophageal Doppler monitoring (ODM)
Trial: 21873370
Drug: Intraoperative goal-directed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative goal-directed fluid therapy (GDT)
Trial: 15616893
Drug: Vitamin K2
RxNorm normalized name: Vitamin K2
DrugBank: Menaquinone 6 (DB14936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K2 (15 mg per day) in addition to GC (group B)
Trial: 12777950
Drug: Insulin treatment
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin treatment adjustment
Trial: 12777950
Drug: NG‐monomethyl‐l‐arginine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NG‐monomethyl‐l‐arginine
Trial: 8723170
Drug: Cilazapril 5
RxNorm normalized name: cilazapril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazapril 5 mg daily (n = 9)
Trial: 8723170
Drug: Hydrochlorothiazide 25
RxNorm normalized name: hydrochlorothiazide 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 25 mg daily (n = 8)
Trial: 3892993
Drug: ALB (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALB (80 g albumin on the day of operation and 20 g for the following 3 days)
Trial: 21715107
Drug: memantine 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: memantine 15 mg bid
Trial: 21715107
Drug: memantine 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: memantine 30 mg bid
Trial: 19564368
Drug: 320 mg
RxNorm normalized name: aspirin 320 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 320 mg gemifloxacin as an oral tablet without probenecid
Trial: 19564368
Drug: 320 mg
RxNorm normalized name: aspirin 320 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 320 mg gemifloxacin as an oral tablet with 4.5 g probenecid divided in eight oral doses
Trial: 3300408
Drug: nalbuphine 10
RxNorm normalized name: nalbuphine 10 mg/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nalbuphine 10 mg
Trial: 3300408
Drug: nalbuphine 20
RxNorm normalized name: nalbuphine 20 mg/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nalbuphine 20 mg
Trial: 3555569
Drug: pethidine 100
RxNorm normalized name: Pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pethidine 100 mg
Trial: 29045207
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of tofacitinib administered orally twice daily